AMAG Pharmaceuticals, Inc. Forecasted to Post FY2022 Earnings of ($0.44) Per Share (AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Jefferies Group issued their FY2022 earnings per share (EPS) estimates for AMAG Pharmaceuticals in a report released on Thursday. Jefferies Group analyst E. Yang anticipates that the specialty pharmaceutical company will post earnings of ($0.44) per share for the year. Jefferies Group currently has a “Buy” rating and a $16.00 price target on the stock.

Several other brokerages have also commented on AMAG. B. Riley reaffirmed a “hold” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research report on Tuesday, January 16th. Cowen dropped coverage on shares of AMAG Pharmaceuticals in a research report on Thursday. Morgan Stanley lowered their price objective on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, November 3rd. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $15.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, January 18th. Finally, Janney Montgomery Scott reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. AMAG Pharmaceuticals presently has an average rating of “Hold” and an average target price of $21.82.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at $18.50 on Monday. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $25.20.

Several institutional investors and hedge funds have recently bought and sold shares of AMAG. Balter Liquid Alternatives LLC purchased a new position in shares of AMAG Pharmaceuticals in the fourth quarter worth about $120,000. Teacher Retirement System of Texas purchased a new position in shares of AMAG Pharmaceuticals in the fourth quarter worth about $162,000. Hartford Investment Management Co. purchased a new position in shares of AMAG Pharmaceuticals in the third quarter worth about $186,000. Two Sigma Securities LLC purchased a new position in shares of AMAG Pharmaceuticals in the fourth quarter worth about $187,000. Finally, 361 Capital LLC purchased a new position in shares of AMAG Pharmaceuticals in the third quarter worth about $197,000.

TRADEMARK VIOLATION NOTICE: “AMAG Pharmaceuticals, Inc. Forecasted to Post FY2022 Earnings of ($0.44) Per Share (AMAG)” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/02/19/amag-pharmaceuticals-inc-forecasted-to-post-fy2022-earnings-of-0-44-per-share-amag.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply